Denali Therapeutics Inc.

Roche Palo Alto LLC

Hoffmann-la Roche Inc.

Novartis Ag

F. Hoffmann-la Roche Ag

Javier De Vicente Fidalgo

Jianwen A Feng

Anthony A Estrada

Zachary Kevin Sweeney

Brian M Fox

Joseph P Lyssikatos

Maksim Osipov

Colin Philip Leslie

Arun Thottumkara

Cheng Hu

Robert A Craig, Ii

Ryan Craig Schoenfeld

Alfonso Pozzan

Jim W Li

Francisco Xavier Talamas

Cinzia Maria Francini

Christopher R H Hale

Anantha R Sudhakar

Giorgio Bonanomi

Katrina W Lexa

Eric Brian Sjogren

Michael Soth

Elbert Chin

Allen John Lovey

Johannes Cornelius Hermann

Hongju Li

Travis Remarchuk

Joshua Paul Gergely Taygerly

Elena Serra

Matthew Michael Hamilton

Ce Wang

Sung-Sau So

Haiying He

Xiaolin Li

Matthew C Lucas

Francisco Javier Lopez-Tapia

Achyutharao Sidduri

Kin-Chun Thomas Luk

Peter Michael Wovkulich

Kenneth Albert Brameld

Romyr Dominique

Shaoqing Chen

Stephen Matthew Lynch

Zhigan Jiang

David Scott Carter

Joshua Jahmil Kennedy-Smith

Peichao Lu

Daniel Mutnick

Xiaojing Michael Wang

Fernando Padilla

Alexey A Rivkin

Xiaohu Zhang

Alfred Sui-Ting Lui

Remy Lemoine

Kristen Lynn McCaleb

Joshua Kennedy-Smith

Folkert Reck

Jianhua Xia

Carmela Napolitano

Wosenu Mergo

Yongjin Xu

Federica Tonelli

Colin Phillip Leslie

Colin Keith Skepper

Counde O'yang

Robert A Ii Craig

Jim Li

Stephen M Lynch

The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.

Compounds, compositions and methods

The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, isotopically enriched analog, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or pharmaceutical composition thereof, and methods of making and using thereof.

LRRK2 inhibitors and methods of making and using thereof

The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.

The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.

The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.

Kinase inhibitors and uses thereof

The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.

Modulators of eukaryotic initiation factor 2B, compositions and methods

The present disclosure relates generally to compounds of formula (I) or a pharmaceutically acceptable salt, prodrug, deuterated analog, tautomer, stereoisomer, or mixture of stereoisomers thereof and their use as LRRK2 inhibitors.

Substituted pyrimidines as LRKK2 inhibitors

The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.

Compounds, compositions, and methods

Compounds having activity as LRRK2 inhibitors are disclosed. The compounds are of formula (I) including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds are also disclosed.

Compound, compositions, and methods

Growing community of inventors

Foster City, CA, United States of America

Javier De Vicente Fidalgo